Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI:10.1080/17512433.2024.2310070

Aayushi Sood, Purnoor Kaur, Omar Syed, Akshit Sood, Wilbert S Aronow, Benjamin Borokhovsky, Vishal Bhatia, Rahul Gupta

{"title":"Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.","authors":"Aayushi Sood, Purnoor Kaur, Omar Syed, Akshit Sood, Wilbert S Aronow, Benjamin Borokhovsky, Vishal Bhatia, Rahul Gupta","doi":"10.1080/17512433.2024.2310070","DOIUrl":null,"url":null,"abstract":"Introduction: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.Areas covered: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action. Clinical trials demonstrate its effectiveness in glucose control, weight reduction, and its potential impact on diabetes, obesity, NASH, and cardiovascular risks.Expert opinion: Tirzepatide shows promise in diabetes treatment, offering glucose control and weight loss. It also holds potential for addressing comorbidities. However, cautious use is vital due to potential adverse effects and contraindications, including hypersensitivity reactions, pregnancy, and breastfeeding precautions. This review underscores tirzepatide as a valuable addition to diabetes therapies, with evolving prospects for enhanced patient outcomes as research advances.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"235-246"},"PeriodicalIF":3.6000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2024.2310070","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.

Areas covered: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action. Clinical trials demonstrate its effectiveness in glucose control, weight reduction, and its potential impact on diabetes, obesity, NASH, and cardiovascular risks.

Expert opinion: Tirzepatide shows promise in diabetes treatment, offering glucose control and weight loss. It also holds potential for addressing comorbidities. However, cautious use is vital due to potential adverse effects and contraindications, including hypersensitivity reactions, pregnancy, and breastfeeding precautions. This review underscores tirzepatide as a valuable addition to diabetes therapies, with evolving prospects for enhanced patient outcomes as research advances.

查看原文本刊更多论文

糖尿病护理的革命：揭示替扎帕肽在血糖控制及其他方面的潜力。

引言糖尿病是一项全球性的公共卫生挑战，发病率不断上升。本综述探讨了当前对糖尿病的认识、诊断和管理指南、经济影响以及作为主要方法的生活方式调整：以药物干预为重点，我们讨论了 GLP-1 激动剂和 GLP/GIP 激动剂在糖尿病管理和降低心血管风险方面的作用。其中重点介绍了新型药物替扎帕肽（Tirzepatide）的独特作用机制。临床试验证明了其在控制血糖、减轻体重方面的有效性，以及对糖尿病、肥胖症、NASH 和心血管风险的潜在影响：专家观点：替唑帕肽有望用于糖尿病治疗，可控制血糖和减轻体重。专家观点：替泽帕肽在糖尿病治疗中大有可为，它能控制血糖和减轻体重，还具有治疗合并症的潜力。然而，由于潜在的不良反应和禁忌症，包括超敏反应、妊娠和哺乳期注意事项，谨慎使用至关重要。这篇综述强调了替哌肽作为糖尿病疗法的重要补充，随着研究的深入，它有望改善患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.